Dose-seeking and Efficacy Study of the Combination of the BRAF Inhibitor Vemurafenib and High-dose Interferon Alfa-2b for Therapy of Advanced Melanoma

Trial Profile

Dose-seeking and Efficacy Study of the Combination of the BRAF Inhibitor Vemurafenib and High-dose Interferon Alfa-2b for Therapy of Advanced Melanoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Feb 2017

At a glance

  • Drugs Interferon alpha-2b (Primary) ; Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Feb 2017 Status changed from recruiting to active, no longer recruiting.
    • 14 Apr 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 19 Sep 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top